Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PePS2: Pembrolizumab in NSCLC Patients with ECOG Performance Status 2
2015-002241-55Phase 2Unknown
- Sponsor
- University of Birmingham
- Start
- Feb 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by University of Birmingham. Primary endpoints: Co-primary: Health-related quality of life during pembrolizumab treatment and Co-primary: Second co-primary outcome (unspecified). Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2015-002241-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002241-55.